The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to taking Ozempic: It may help manage chronic kidney disease (CKD). On January ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.